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Abstract
Amiloride-sensitive, epithelial Na+ channel (ENaC)-mediated, active absorption of Na+ is elevated
in the airway epithelium of cystic fibrosis (CF) patients, resulting in excess fluid removal from the
airway lumen. This excess fluid/volume absorption corresponds to CF transmembrane regulator-
linked defects in ENaC regulation, resulting in the reduced mucociliary clearance found in CF
airways. Herein we show that INO-4995, a synthetic analog of the intracellular signaling molecule,
D-myo-inositol 3,4,5,6-tetrakisphosphate, inhibits Na+ and fluid absorption across CF airway
epithelia, thus alleviating this critical pathology. This conclusion was based on electrophysiological
studies, fluid absorption, and 22Na+ flux measurements in CF airway epithelia, contrasted with
normal epithelia, and on electrophysiological studies in Madin-Darby canine kidney cells and 3T3
cells overexpressing ENaC. The effects of INO-4995 were long-lasting, dose-dependent, and more
pronounced in epithelia from CF patients vs. controls. These findings support preclinical
development of INO-4995 for CF treatment and demonstrate for the first time the therapeutic
potential of inositol polyphosphate derivatives.
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CYSTIC FIBROSIS (CF) airway epithelia show hyperabsorption of liquid due to mutations
in the gene for the CF transmembrane conductance regulator (CFTR) resulting in Cl− channel
malfunction and dysregulation of Na+ absorption through the amiloride-sensitive epithelial
Na+ channel (ENaC) (23,45,46). ENaC, the rate-limiting step in the regulation of Na+
absorption across epithelia, helps maintain airway surface liquid volume/depth (20). Excess
fluid/volume absorption correlates with defects in ENaC regulation and plays a primary role
in the reduced mucociliary clearance found in CF airways. Mucus clearance is an important
defense mechanism that protects the airways from infections (22), and defective mucus
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clearance is associated with the repeated pulmonary infections in CF patients that ultimately
result in organ failure.
In CF airway epithelia, ENaC-mediated Na+ absorption is increased 100–300% (2). Initially,
this was attributed to a direct molecular interaction between CFTR and ENaC. However, no
such association was found and is unlikely, because the relationship between ENaC activity
and CFTR function is reversed in the sweat glands. Recent studies have demonstrated that
electrical potential (34), intracellular Cl− concentration (24), or electrical coupling between
Cl− and Na+ fluxes (16) could all mediate the inhibition. Therefore, the agents that modulate
non-CFTR Cl− channel activity, such as Ca2+-activated Cl− channels in CF tissue, could
secondarily regulate ENaC.
Inhibition of Na+ flux through ENaC is predicted to completely compensate for the CFTR
defect in restoration of airway surface liquid (ASL) in a mathematical simulation of airway
epithelial cells (36,37). In support of this, amiloride, an extracellular blocker of ENaC,
temporarily increased mucociliary clearance in clinical trials (48). Problematically, the
duration of amiloride action in vivo is very brief (15–30 min), thereby limiting its therapeutic
efficacy. This transience is due in part to the diffusion and dilution of effective concentrations
of extracellular amiloride. The relatively short half-life of its target, ENaC, in the plasma
membrane (40) may also contribute to its brief duration of action.
Some of the >30 naturally occurring inositol polyphosphates (IPs) and phosphoinositides
(18,28,32,42) are ion channel regulators (5,12–15,18,19,21,35,39,50–52). Whereas D-myo-
inositol 1,4,5-trisphosphate [Ins(1,4,5)P3], a trigger for [Ca2+]i release, is the most widely
recognized (17), inositol tetrakisphosphates also modulate ion channel activities, including
Cl− and K+ channels (12,18,21,50). A particular inositol phosphate, Ins(3,4,5,6)P4, targets
Cl− channels in epithelia (5,13,14). IPs are highly charged, thereby making them unlikely to
cross membranes. Thus membrane-permeant forms have been developed that enable
intracellular delivery, which recapitulates the ion channel modulating activity of endogenous
IPs (27,41,50).
In contrast to extracellularly acting agents directed against the extracellular domain of ion
channel pores, membrane-permeant IP analogs modulate ion channel activities from inside the
cell. Analogs of slowly metabolized IPs can have an extended duration of action. Therefore,
they have the potential for prolonged activity in contrast to the more rapidly eliminated
extracellularly active compounds. We previously observed that direct application of a
membrane-permeant analog of Ins(3,4,5,6)P3, INO-4995 (Fig. 1), to human nasal airway
epithelia reduced the amiloride-inhibitable basal short-circuit current (Isc) (49). This effect was
long lasting but reversible after 48 h. In the current study, we investigated the ionic basis for
the inhibition of Isc and probed whether it corresponded to therapeutically meaningful changes
in fluid flux as assessed from open-circuit fluxes of 22Na. Thus, in the absence of INO-4995,
the mucosa-to-serosa flux of 22Na across CF airway epithelia was inhibited by amiloride, but
this amiloride sensitivity was abolished by INO-4995. INO-4995 had no effects on Na+ fluxes
across non-CF airway epithelia. These effects of INO-4995 corresponded to slowing of the
fluid absorption rate that portend therapeutic efficacy in CF. In related studies in a mouse nasal
potential difference (PD) model, INO-4995 lowered abnormal nasal PD in gut-corrected CF
mice (8), further substantiating its therapeutic potential.
METHODS
Materials
Surgically excised nasal polyps were obtained from volunteers in collaboration with Dr. Bonnie
Ramsey at Children’s Hospital, Seattle, WA, and Dr. Ludwig Allegra at the Northwest Nasal
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Sinus Center. The patients provided informed consent before we obtained the tissue specimens.
All protocols complied with institutional guidelines of, and were approved by, the Institutional
Review Board at Children’s Hospital in Seattle. INO-4995, IPs, phosphate/ PM, and other
membrane-permeant IP analogs were obtained from SiChem. All other reagents were provided
by Sigma-Aldrich unless otherwise indicated.
CF human nasal epithelial (CFHNE) and non-CF nasal epithelial (HNE) cell cultures were
cultured and prepared for Ussing studies as described elsewhere (49).
Monolayer preparation for Ussing studies
Epithelial cells (passage 2 or 3) were prepared for Ussing chamber and fluid transport studies
using Snapwell permeable supports (0.4 μm pore size; Corning Costar, Cambridge, MA) coated
with 1 μg/cm2 Vitrogen. Cells were plated at 105 cells/cm2 in keratinocyte serum-free media.
After 2 days, the media were changed to bronchial epithelial growth medium (BEGM), a 1:1
mixture of DMEM (MediaTech/Cellgro, Herndon, VA), and bronchial epithelial basal media
(BEBM) (Clonetics/Biowhittaker, Walkersville, MD), with the following supplements:
hydrocortisone (0.5 μg/ml), insulin (5 μg/ml), transferrin (10 μg/ml), epinephrine (0.5 μg/ml),
triiodothyronine (6.5 ng/ml), bovine pituitary extract (52 μg/ml), EGF (0.5 ng/ml), all-trans
retinoic acid (50 nM, Sigma), penicillin (100 U/ml, Sigma), streptomycin (0.1 mg/ml, Sigma),
nonessential amino acids (1×, Sigma), and fatty acid-free bovine serum albumin (3 μg/ml,
Sigma). Cells were grown in the BEGM for 1 wk, at which point an air-liquid interface (ALI)
culture system was initiated (30). The cells were grown for 2 wk at ALI and fed every other
day basolaterally until use in the Ussing chamber (usually 7–10 days).
Ussing chamber studies
Monolayers of HNE and CFHNE were mounted in modified Ussing chambers (Physiological
Instruments, San Diego, CA) with the use of a Ringer bicarbonate solution containing (in mM)
115 NaCl, 2.4 K2HPO4, 0.4 KH2PO4, 1.2 MgCl2, 1.2 CaCl2, 25 NaHCO3, and 10 glucose,
unless otherwise indicated. Experiments were carried out at 37°C, and the pH was adjusted to
7.4 by being gassed with 95% O2-5% CO2. After an open-circuit equilibration period of 10
min, the transepithelial PD was recorded, the cells were voltage clamped at 0 mV, and the
resulting Isc was continuously recorded. A periodic bipolar voltage pulse monitored resistance
calculated using Ohm’s law. In acute experiments, drugs were added to the apical or basolateral
compartment, as indicated, and the changes in response were recorded. In preincubation
experiments, a compound dissolved in 100 μl of media was added to the apical surface of
monolayers growing on Snapwells. After a 2-h incubation period at 37°C in a CO2 incubator,
the apical media containing compound was removed, and monolayers were washed with
BEGM and returned to ALI for the indicated time before being mounted in Ussing chambers.
22Na+ flux
Monolayers of CFHNE were pretreated with either 20 μM INO-4995 or 2-h vehicle control
for 17–22 h before being tested. Monolayers were mounted in Ussing chambers, and PD and
resistance were monitored under open-circuit conditions while ion fluxes were measured as
described previously (26). A quantity of 10 μCi of 22Na and 45 μCi of 36Cl were added to
either the mucosal or serosal chamber. Aliquots (3 ml) were removed from the downhill
chambers for counting at 5-min intervals. After 20 min, 100 μM amiloride was added to the
mucosal chamber and aliquots were removed for an additional 20 min. Ion flux was calculated
as described.
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Outside-out patches were configured from 3T3 cells stably expressing rat αβγ-ENaC. Patches
from 3T3 containing near-silent ENaCs were activated with trypsin (4) before INO exposure.
The temperature was ~23°C. The 3T3-cell bath solution contained (in mM) 150 Li+-aspartate,
2 MgCl2, 1 CaCl2, and 5 HEPES, titrated to pH 7.30 with LiOH. Calculated osmolarity was
314 mosmol/l. The 3T3-cell pipette solution contained (in mM) 120 Tris-aspartate, 20 NaCl,
3 MgATP, 0.2 Na2GTP, 0.1 CaCl2, 1 EGTA, and 5 HEPES titrated to pH 7.10 with NaOH.
Free [Ca2+] was ~43 nM, and calculated osmolarity was 295 mosmol/l.
Apical permeabilization and Na+-K+-ATPase activity
Nystatin is a pore-forming antimycotic that enables permeabilization of the cell membrane to
monovalent ions: Na+, K+, and Cl− (23). Apical nystatin (360 μg/ml) was applied to the solution
that bathed the apical compartment at the indicated time. Cytosolic levels of Na+ (25 mM)
were achieved in the bathing solutions by replacing a portion of the NaCl with NMDG-C (145
mM). After permeabilization, the increase in Isc is primarily due to Na+ movement driven by
the Na+-K+-ATPase that is completely inhibited by basolateral application of 100 μM ouabain.
The composition of the buffer was as follows (in mM): 145 NMDG-Cl, 25 Na+, 5 K+, 1.2
Ca2+, 1.2 Mg2+, 25 HCO3−, 3.3 H2PO4− , 0.8 HPO42−, and 10 glucose, pH 7.4.
To create a K+ gradient to evaluate for effects on basolateral K+ channels, the buffers were as
follows: basolateral compartment (in mM) 120 K-gluconate, 4 Ca-gluconate, 4 MgSO4, 0.8
K2HPO4, 3.3 KH2PO4, 25 NaHCO3, and 10 glucose; and apical compartment (in mM) 120
Na-gluconate, 4 Ca-gluconate, 4 MgSO4, 0.8 K2HPO4, 3.3 KH2PO4, and 25 glucose.
Blue Dextran fluid transport assay
Blue Dextran (BD) is a 2,000,000-MW compound that is not absorbed by cells and does not
move across tight junctions. BD stock solution was prepared with HEPES-modified Ringer
buffer (HMRB) (2 mg BD/ml buffer). INO-4995 was solubilized in HMRB [pH 6.7, containing
(in mM): 135 NaCl, 1.2 CaCl2, 1.2 MgCl2, 2.4 K2HPO4, 0.6 KH2PO4, 10 HEPES, and 10
glucose (~285 mosmol/l)] containing ~1 μM BD. The final concentration of vehicle was 0.1%
[1:1, DMSO+DMSO containing 5% (wt/vol) Pluronic F-127]. Two hundred microliters of the
BD (1 μM) solution containing vehicle or compound were added apically, and monolayers
were incubated (Forma model 3956 set on maximum humidity setting) for 18 h. Control plates
with media and impermeable membranes showed no loss of volume over 18 h under these
conditions. Basolateral buffer consisted of BEGM (~300 osmol/l). After 18 h, 60 μl of the
remaining apical buffer were collected for analysis. A standard concentration curve was
obtained from the optical density, at 660 nm, of a serial dilution of 10 μM BD in HMRB in a
96-well plate with the use of a Packard Spectracount. The concentration of BD ([BD]) in the
samples was extrapolated from the BD standard curve using Packard I-Smart software. The
increase in [BD] from the starting value of 1 μM was taken as the magnitude of volume
absorption. Absorption rate was calculated by dividing the Δvolume by time normalized to
monolayer surface area.
RESULTS
INO-4995 inhibits sodium flux
We have previously shown that direct exposure of CF human nasal epithelial (CFHNE)
monolayers to INO-4995 results in a progressive decline in amiloride inhibitable Isc.
Furthermore, a pulsed exposure to INO-4995 inhibits basal Isc in CF airway epithelia for >24
h (49). Although Isc reflects the sum of all transepithelial ion flux, the elevated basal Isc in CF
tissue is attributed to abnormally high levels of mucosal to serosal Na+ absorption (29). To test
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whether INO-4995 inhibition of Isc was due to Na channel inhibition, we performed several
steps. First, we compared the effects of INO-4995 on amiloride-inhibitable Isc in human CF
vs. non-CF nasal epithelium. Second, we tested whether INO-4995 inhibits Isc in MDCK cells
overexpressing ENaC. Third, we tested whether INO-4995 inhibits ENaC in outside-out
patches from 3T3 cells overexpressing rat αβγ-ENaC. Fourth, we tested the effect of INO-4995
on transepi-thelial 22Na+ flux under open circuit conditions. Fifth, we determined the
contribution of the Na+-K+-ATPase to INO-4995 inhibition of Isc. Finally, we determined
INO-4995 effects on the fluid absorption rate across airway epithelia.
Prolonged effects of INO-4995 on CFNHE electrophysiology
We exposed monolayers apically to INO-4995 for 2 h, then washed and returned the cultures
to ALI for 22 h before mounting the monolayers in Ussing chambers for testing. At this time,
Isc was reduced (Fig. 2A), demonstrating a prolonged duration of action. We repeated this
experiment with multiple doses of INO-4995 to generate the dose-response curve depicted in
Fig. 2B. INO-4995 dose-dependently inhibited the basal Isc in CFHNE (EC50 = 10 μM; Fig.
2B). In addition to the vehicle controls, additional controls included pretreatment with
phosphate PM ester (Pi/PM), or structurally related analogs with fewer phosphates. IP analogs
that did not have the membrane-permeating protecting groups were likewise without effect. A
series of membrane-permeant IP analogs ranged from having no effect to having similar effects
to INO-4995 with potency corresponding to the phosphorylation pattern and the nature of the
substitutions at positions 1 and 2. INO-4995 had no apparent deleterious effects on tight
junction integrity, as resistance did not decrease (Fig. 2C), even with 500 μM INO-4995. In
other experiments, repeated exposures over a period of 4–8 days likewise did not reveal delayed
or cumulative adverse effects on monolayer integrity.
Comparison of INO-4995 effects in CF vs. non-CF epithelia
We compared the dose-dependent inhibition of amiloride-inhibitable Isc 22 h after incubation
with INO-4995 in CF vs. non-CF tissue. INO-4995 inhibits basal Isc in CF tissue but has
minimal effect on tissue from non-CF donors (Fig. 2B). For instance, 10 μM INO-4995 inhibits
Isc by 45% in CF epithelial cells but only 5% in non-CF epithelial cells. This difference is
independent of the magnitude of the basal Isc.
INO-4995 inhibits ENaC activity in overexpressing cell lines
MDCK cells overexpressing ENaC (45) allowed more direct testing of the effect of INO-4995
on Na+ channel activity. These cells exhibit an unusually high basal Isc that is inhibitable with
amiloride and therefore are a good model for CF epithelia. In this model system, as in human
airway CF epithelia, ENaC activity is responsible for most of the elevated basal Isc. INO-4995
(5 μM) preincubation inhibited basal Isc measured 24 h later in the ENaC-overexpressing
MDCK cells in much the same manner as in the CF airway epithelia (Fig. 3). The majority
(91%) of the INO-4995 effect is attributable to the amiloride-inhibitable portion of the current
supporting the hypothesis that INO-4995 inhibits ENaC (Fig. 3B).
The effect of INO-4995 on ENaC activity in outside-out excised patches was measured in 3T3
cells stably overexpressing rat αβγ ENaC subunits. Before INO-4995 exposure, the channel
conductance and sensitivity to block with amiloride confirmed ENaC identity and patch
configuration in this expression system (3,4). INO-4995 (20 μM) applied in the bath inhibited
ENaC in this experiment in eight of nine patches but was without effect on unitary current
amplitude (data not shown). A representative trace depicting single-channel transitions is
depicted in Fig. 3C, and the change in open probability is depicted in Fig. 3, D and E.
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INO-4995 effects on Na+ flux in airway epithelia was tested under open circuit conditions. No
effects on electrical parameters or ion flux were seen in initial experiments using up to 50 μM
INO-4995 on healthy bovine trachea in keeping with specificity of the compound for CF tissue.
In contrast, a 2-h pulsed exposure to 20 μM INO-4995 17–22 h before testing resulted in
inhibition of basal open circuit PD in human CF nasal epithelia. Corresponding changes
in 22Na+ mucosal to serosal and serosal to mucosal flux are shown in Table 1. Both serosal to
mucosal and mucosal to serosal amiloride inhibitable 22Na+ flux were absent in INO-4995-
treated monolayers, whereas amiloride inhibited serosal-to-mucosal 22Na flux in untreated
cells. These results are consistent with amiloride-sensitive fluid absorption being present
normally, but being abolished by treatment with INO-4995.
In well-differentiated CFHNE monolayers, the major pathway for transcellular movement of
Na+ is apical entry via ENaC and basolateral exit via Na+-K+-ATPase. Consequently, apical
application of amiloride (100 μM) or basolateral addition of the Na+-K+-ATPase inhibitor
ouabain (100 μM) completely inhibited the high basal Isc we observed in CFHNE cultures. To
exclude the possibility that the basolateral Na+-K+-ATPase contributed to INO-4995 inhibition
of basal Isc, we tested the effect of INO-4995 on the ouabain-sensitive current in apically
permeabilized monolayers. We monitored spontaneous Isc for 10 min to assess the effect of
INO-4995 on amiloride-inhibitable current. As shown in Fig. 4A, a 2-h preincubation with 10
μM INO-4995 resulted in a typical decrease of basal current measured 4 h later. Amiloride
(100 μM) was added to assess the contribution of ENaC to basal Isc. We then exposed the apical
surface of CFHNE monolayers to nystatin, a pore-forming antimycotic that enhances
permeability to monovalent ions. The Na+-K+-ATPase inhibitor, ouabain, completely inhibited
the resulting increase in Isc after apical permeabilization with nystatin. We observed no
differences in INO-4995 pretreated monolayers vs. controls after amiloride addition or apical
permeabilization. The results show that INO-4995 has little to no effect on ouabain-inhibitable
current (Fig. 4) and supports the hypothesis that INO-4995 inhibits basal Isc through modulation
of ENaC activity and not Na+-K+-ATPase activity.
In a different protocol, we added amiloride after nystatin to determine whether the entire
difference in basal Isc between INO-4995-pretreated monolayers and control monolayers could
be eliminated by apical permeabilization (Fig. 4B). Monolayers were exposed to 10 μM
INO-4995 for 2 h as in Fig. 2 and Ussing chamber recordings carried out 22 h later. We
monitored basal Isc for 25 min, whereupon apical addition of nystatin eliminated the difference
between INO-4995 pre-treated monolayers and controls after a brief period of equilibration,
demonstrating that the target of the INO-4995 action was located in the apical membrane.
Amiloride had very little effect when added after nystatin, but addition of ouabain brought the
Isc to zero, confirming the success of the nystatin permeabilization and demonstrating again
that INO-4995 had no apparent effect on Na+-K+-ATPase.
To further probe whether there might be an effect of INO-4995 on basolateral K+ channel
activity, a K+ gradient was applied to monolayers apically permeabilized with nystatin after
pretreatment with 10 μM INO-4995 as in the experiments described above. As shown in Fig.
4C, the current driven by the K+ gradient was similar in both INO-4995-treated monolayers
and controls.
INO-4995 inhibits fluid absorption
To ascertain the therapeutic relevance of these electrophysiological observations, we evaluated
the ability of compounds to inhibit fluid absorption measured directly. The assay consisted of
monolayer cultures of polarized CF nasal epithelia exposed to an apical buffer containing test
compounds and a known concentration of the nonpermeable BD, using a modification of a
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protocol described by Matsui and coworkers (30). The observed absorption rates ranged from
4 to 6 μl·cm−2 · h−1, consistent with values reported for CF tissue elsewhere (20). We used
amiloride, a blocker of the Na+ channel, ENaC, to assess the ability of this assay to measure
relevant changes in fluid secretion. Accordingly, blocking ENaC with amiloride should
significantly reduce fluid absorption. As anticipated, amiloride (continuously present for the
duration of the 18-h incubation period) inhibits fluid absorption measured by the BD assay
(Fig. 5A) in a dose-dependent fashion.
We hypothesized that because INO-4995 blocks Na+ flux, it would inhibit fluid absorption.
Testing this, we exposed well-differentiated monolayer cultures of CFHNE to an apically
applied buffer containing INO-4995 and BD (Fig. 5). The EC50 of the effect is ~20 μM and
closely parallels the effect on basal Isc, suggesting that INO-4995 affects both parameters. Our
results show that INO-4995 inhibits fluid absorption in CF nasal airways, resulting in greater
fluid volumes on the apical surface of the epithelia, indicating that INO-4995 could be effective
in treating the pulmonary defect in CF.
INO-4995 inhibition of fluid absorption persists for 42 h
The residence time of aerosolized drugs in airways is limited by expulsion, absorption, and
hydrolysis. This may contribute to the short duration of action of extracellularly acting agents,
such as amiloride or purinergic agonists (38,54). In contrast, membrane-permeant analogs of
IP are not subject to those factors once inside the cell. Therefore, we compared the duration of
the effect on fluid absorption following pulsed exposure to compounds. We compared the long-
term effect of pulsed exposure to 50 μM INO-4995 (Fig. 5C) to that of amiloride. The data
show that INO-4995 exerted prolonged effects on fluid absorption. After a 2-h exposure,
INO-4995 continues to affect fluid levels up to 42 h after exposure. In contrast, amiloride
effects are short lived, vanishing on removal from surface liquid so that, as expected, no residual
effect of amiloride contact is detectable 42 h after exposure (Fig. 5C). On the basis of these
results, INO-4995 is likely to be a much more effective therapeutic than amiloride due to
prolonged duration of action.
DISCUSSION
An increase in basal Isc is a characteristic of CF airway epithelia that has been linked to Na+
hyperabsorption, reduced ASL fluid levels, and disease severity (20,23,30). Herein we have
demonstrated that a prodrug based on a derivative of Ins(3,4,5,6)P4, INO-4995, reduces basal
Isc, Na+ flux, and fluid absorption in human CF nasal epithelia. This effect was specific for CF
tissue since INO-4995 had very little effect on Isc in non-CF tissue. The inhibition is dose
dependent and long lasting. INO-4995 blocked fluid absorption and Isc with similar dose
dependency, suggesting that the effects on Na+, Isc, and fluid absorption are interrelated. The
potency of a transient exposure to INO-4995 is comparable to that of continuous exposure to
amiloride in inhibiting basal Isc and fluid absorption. In contrast to amiloride, INO-4995
inhibition persists for at least 42 h after the removal of compound from the extracellular
compartment. In another experiment, a 2-h exposure to 100 μM INO-4995 resulted in reduced
Isc 4 days later (data not shown). The actions of extracellularly acting, aerosolized drugs are
limited by expulsion, hydrolysis, and internalization contributing to the short-term effects of
agents, such as amiloride and purinergic agonists. In contrast, membrane-permeant analogs of
IPs are not subject to these factors once absorbed intracellularly by the mucosal epithelia.
The target of INO-4995, resulting in inhibition of basal Isc, is located at the apical membrane.
Apical membrane permeabilization of monolayers eliminated the Isc differential between
INO-4995 pretreated monolayers and control. There was no inhibition of basolateral Na+-K+-
ATPase activity after INO-4995 treatment. Likewise, K+ currents in monolayers apically
permeabilized were unchanged in the INO-4995-treated monolayers in the presence of a K+
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gradient (Fig. 4C). These data indicate that INO-4995 inhibits Na+ absorption through an
apical, amiloride-sensitive channel, probably ENaC. This is supported by the following data.
First, the elevated basal Isc characteristic of CF tissue that is inhibited by INO-4995 is primarily
due to absorption of Na+ via ENaC. Second, INO-4995 inhibited the amiloride-sensitive Isc in
MDCK cells overexpressing ENaC where the elevated basal Isc is attributable to ENaC. Third,
INO-4995 inhibited current recorded via 2-electrode voltage clamp in ENaC transfected
Xenopus oocytes (S. Gabriel, unpublished observations). Fourth, INO-4995 inhibited 22Na+
flux in CF human epithelia. Finally, INO-4995 inhibited ENaC currents in outside-out patches
from 3T3 cells overexpressing rat αβγ-ENaC.
INO-4995 does not act in the same manner as amiloride. First, while amiloride acts
extracellularly, INO-4995 acts intracellularly. Second, amiloride action is short-lived and
dependent on the continuous presence of the compound, whereas INO-4995 action is
prolonged. Third, amiloride potency in normal HNE is similar to that in CFHNE. In contrast,
INO-4995 is much more potent in CFHNE than in epithelia from non-CF donors.
INO-4995 reduced the rate of amiloride-inhibitable fluid reabsorption in CF epithelia using a
BD assay. There was a component of the fluid absorption rate that was neither inhibited by
amiloride nor INO-4995. This may reflect evaporative loss or an uncharacterized conductance.
However, the maximum change in the rate of fluid flux with amiloride in the BD assay (2.5
μl· cm−2 · h−1) is very close to the amiloride-inhibitable flux calculated from the 22Na flux
studies (3.3 μl· cm−2 · h−1) assuming isotonicity of transported fluid. Tarran and associates
(47) have shown that fluid absorption rates slow when the height of the ASL falls <20 μm.
However, under the conditions of the current study, the height of the surface fluid remains well
above this level during the entire experiment. Further studies are planned which could
determine whether there are differential effects of INO-4995 with varying fluid levels. It should
be noted that an amiloride-sensitive fluid absorption of 3 μl· cm−2 · h−1 is similar to that reported
by others (20) and, if unopposed, would shrink the depth of ASL by 0.5 μm/min. Therefore, if
inhibiting amiloride-sensitive Na+ absorption unmasks an opposing secretory process, then
ASL depth could increase by as much as 0.5 μm/min, causing ASL to double in depth
approximately every 10 to 20 min.
The key to the therapeutic potential of INO-4995 is its prolonged effect that may be due to
slow metabolism of the active form, INO-4913. Ins(3,4,5,6)P4 levels can remain elevated for
hours (50) and are controlled by the reversible Ins(3,4,5,6)P4/InsP5 1-kinase/1-phosphatase
(15) that phosphorylates Ins(3,4,5,6)P4 on the 1 position, generating InsP5. The deesterified
product of the prodrug INO-4995, INO-4913 (Fig. 1), cannot be directly metabolized via this
pathway due to the ether-linked octyl group at the 1 position, contributing to its extended
duration of its action.
We considered the possibility that INO-4995 could be acting through modulation of serine
protease activity, a recently characterized path that modulates ENaC open probability (7).
However, INO-4995 appears to act in a serine protease-independent manner because
monolayers pretreated with 10 μM INO-4995 still exhibited reduced basal Isc relative to control
after the addition of trypsin (data not shown). Moreover, the addition of aprotinin, a serine
protease inhibitor, further reduced basal Isc in INO-4995 pretreated monolayers in an additive
fashion, indicating that the two agents work through separate but complementary mechanisms.
Phosphatidylinositol (PI)3-kinase pathways can regulate ENaC surface expression in renal
epithelia. For instance, Nedd4-2 regulates ENaC expression (31,43,44) and is downstream of
hormone (aldosterone or insulin) triggered serum and glucocorticoid-regulated kinase (Sgk-1)
and PI3-kinase signaling (1,6,11). Certain IPs interfere with PI3-kinase signaling pathways
(12) and may therefore reverse PI3-kinase-mediated Sgk-1 upregulation of ENaC via Nedd4-2.
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INO-4995 may directly modulate ENaC
Herein we have shown that INO-4995 inhibited ENaC open probability in excised outside-out
patches. Although the concentration of INO-4995 in the bath was 20 μM, the compound would
presumably have to cross the patch membrane and be deesterified to generate the active
compound, INO-4913, at the site of action. Therefore, a much more detailed study is underway
to determine the concentration of the relevant compound and pinpoint the site of action.
INO-4995 may indirectly modulate ENaC through actions on Cl− channels. For instance,
INO-4995 is an analog of Ins(3,4,5,6)P4, which modulates Ca2+-activated Cl− channels in
multiple systems (5,19,42,50–52). We have shown that an analog of INO-4995 opens Cl−
channels in whole cell patch-clamp configuration (9), whereas a deesterified form of
INO-4995, INO-4913 opens Cl− channels in a dialyzed cell preparation (10). In addition,
repeated exposure to low doses of INO-4995 enhances the Isc response to ATP, suggesting an
increase in Ca2+-activated Cl− channel activity (33). Others have shown that Ca2+-activated
Cl− channels as well as CFTR activity can modulate Na+ flux via electrochemical coupling
(16,24,25,34). A recent study (53) suggests that both ENaC activity and expression levels are
modulated by Cl− channel-mediated changes in intracellular Cl− levels. However, it is unclear
how that mechanism could account for the inhibition of ENaC measured in excised patches
described herein.
We have demonstrated that the IP analog, INO-4995, reverses physiological processes
associated with pathological function in CF tissue, Na+, and fluid absorption. Thus INO-4995
is a potential treatment for the underlying defect in fluid secretion in CF linked to morbidity
and mortality. Our findings support preclinical development of INO-4995 for the treatment of
CF and represent the first demonstration of the therapeutic significance of a derivative of an
IP signaling molecule. In addition to a potential breakthrough in CF research, our results have
much wider implications for the design of pharmaceuticals targeting intracellular IP and
phosphoinositide signaling cascades.
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INO-4995 and INO-4913. The structure of the pro-drug, INO-4995, is depicted on the right
side of the figure (3). INO-4995 ester groups are hydrolyzed by intracellular esterases releasing
the active compound, INO-4913 (2). INO-4995 and INO-4913 are analogs of the endogenous
signaling molecule, Ins(3,4,5,6)P4 (1).
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Dose dependence of the long-term effect of INO-4995 on spontaneous short-circuit current
(Isc) and resistance in cystic fibrosis (CF) and non-CF airway epithelia. Monolayers of
differentiated CF nasal epithelial cultures were exposed to INO-4995 applied to solution
bathing the mucosal membrane for 2 h. The monolayers were washed and then returned to air-
liquid interface (ALI) for 22 h before being mounted in Ussing chambers for testing. In these
experiments, INO-4995 inhibited the basal Isc in CF human nasal airway epithelia with an
EC50 of 10–20 μM. Vehicle [PBS containing 1% 1:1, DMSO+DMSO containing 5% (wt/vol)
Pluronic F-127] present in both treatment and control for the 2-h exposure period. A:
representative experiment contrasting basal Isc in monolayers incubated for 2 h with two
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different concentrations of INO-4995 vs. vehicle control and measured 22 h after exposure: 6
traces are shown, 3 from monolayers pretreated with 40 μM INO-4995 (dotted line), 1 from
monolayer pretreated with 10 μM INO-4995 (dashed line), and 2 vehicle-treated controls (solid
lines). B: comparison of the dose dependence of INO-4995 inhibition of basal Isc in human
nasal epithelia (CF vs. non-CF). Control CF (n = 14); control non-CF (n = 16). Differences
between the means of the CF vs. non-CF samples were evaluated for statistical significance
via Student’s unpaired t-test. *P = 0.035; **P = 0.0012; ***P < 0.001. C: comparison of various
doses of INO-4995 on transepithelial resistance in CF human nasal epithelia. Data are means
± SD; n = 3–17 monolayers.
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INO-4995 inhibits basal Isc in Madin-Darby canine kidney (MDCK) cells overexpressing
human epithelial Na+ channels (hENaC). A: representative Isc tracings are shown for MDCK
cells incubated for 22 h in INO-4995 (100 μM; dashed line) or vehicle control (solid line).
Amiloride (10−4 M) was added to both monolayers after baseline currents were recorded and
the decrease in Isc was recorded. Amiloride was then washed out of the luminal solution, and
currents returned to basal values that were again sensitive to inhibition by amiloride (10−4 M).
The amiloride-sensitive current represents ~82% of the baseline current in control cells and
91% in INO-4995-treated cells, demonstrating that the major current in both of these conditions
is mediated by ENaC. B: summary data of the amiloride-sensitive current in INO-4995 treated
monolayers (open bars) and vehicle-treated monolayers (solid bars). All values are means ±
SE, n = 8. INO-4995 incubation results in a significantly reduced amiloride-sensitive current
in these cells compared with vehicle-treated control cells (P < 0.01). C: patch-clamp recording
of an excised outside-out patch from a 3T3 cell expressing rat αβγ-ENaC subunits. Channel
transitions from selected consecutive traces at −60 mV are shown before (Control, sweep 13)
and during bath application of INO (20 μM, INO, sweeps 14–18). An abrupt decrease in channel
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activity was observed within 1.5-min drug exposure. Inset: recording from the same patch (−40
mV) showing bath amiloride (10 μM, horizontal line) reversibly inhibited channel activity;
horizontal and vertical scale bars are 5 s and 0.2 pA, respectively. Slope conductance (7.6
picoSiemens in 150 mM Li+) and amiloride-inhibited channel activity confirmed ENaC
identity. Dashed lines through traces represent closed-channel current level. D: open channel
diary of recording shown in C. Open probability (Po) ranged from 0.13 to 0.80 (sweeps 1-13,
control) and showed no evidence of time-dependent reduction in Po before drug exposure (INO,
see bar). E: summary effects of INO on ENaC activity. Channel activity (NPo, N = number of
channels) was reduced ~28% in the presence of INO relative to control (Control NPo = 2.55 ±
0.56 vs. INO NPo = 1.84 ± 0.58, means ± SE; n = 9, P = 0.042). Solid lines connect symbols
of NPo recorded before and after 1- to 5-min bath exposure to INO (20 μM) from the same
patch. Experiments were performed at ~23°C.
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Effect of INO-4995 on basal Isc in apically permeabilized monolayers. A: amiloride inhibits
basal Isc and obliterates difference between control and INO-4995-treated monolayers. Isc
responses in monolayers pretreated with INO-4995 are contrasted with control monolayers
incubated with vehicle control. Nystatin was used to permeabilize the apical membrane, as
described in METHODS. INO-4995 (10 μM) was administered to the monolayers for 2 h,
removed, and cells were mounted in Ussing chambers 4 h later. Subsequent permeabilization
of the apical membrane with nystatin evokes an identical shift in Isc in both control (solid line)
and INO-4995-treated (dashed line) monolayers. This current is completely inhibitable by
blocking the Na+-K+-ATPase with ouabain. B: effect of INO-4995 is abolished after
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permeabilization of the apical membrane with nystatin. Subsequent change following
amiloride (100 μM) addition is indicative of effectiveness of the nystatin permeabilization.
Ouabain-sensitive current is indistinguishable between INO-4995-treated (dashed line) and
control (solid line) monolayers. C: no difference is seen with INO-4995 pretreatment (10 μM,
2 h, tested after 22 h) on Isc across apically permeabilized monolayers with a basolateral to
apical K+ grandient. Amilo-ride (100 μM) was present during the experiment. Nystatin (360
= μg/ml) was added at the indicated time.
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INO-4995 inhibits fluid absorption in CF airway epithelia. A: dose response of amiloride
inhibition of absorption rate in cultured CF human nasal epithelial cells. Average absorption
rates were calculated from Δ [Blue Dextran] over 18 h of amiloride exposure, as described in
METHODS. Data are means ± SD (n = 6 for each condition). Control: vehicle. *P < 0.05;
**P < 0.001; ***P < 0.005. B: dose response curve for INO-4995 inhibition of fluid absorption
measured with the Blue Dextran assay, as described in METHODS. Data show the INO-4995
dose-dependent change in fluid absorption rates from the control values, means ± SD. Control:
vehicle [1% 1:1, DMSO+DMSO containing 5% (wt/vol) Pluronic F-127] present during the
2-h exposure period. Differences between means of treated and control samples were evaluated
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for statistical significance using Student’s unpaired t-test: *P = 0.038; **P = 5.1 × 10−6;
***P = 1.8 × 10−8. C: comparison of the effect of a 2-h exposure with 50 μM INO-4995 vs.
50 μM amiloride on absorption rate after 42 h in cultured CFHNE. Data are means ± SD for
n = 6 monolayers. Statistical significance (P = 0.0007) vs. control was determined by Student’s
unpaired t-test. Vehicle [Krebs-Ringer containing 0.1% 1:1, DMSO+DMSO containing 5%
(wt/vol) Pluronic F-127] present in both treatment and control for the 2-h exposure period.
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Table 1
INO-4995 inhibits 22Na movement across CF airway epithelia
Control (n = 5) INO-4995 Treated (n = 4)
Before After amiloride Before After amiloride
JNa, m→s 1.62 ± 0.42 1.23 ± 0.34* 1.27 ± 0.28 1.31 ± 0.23
JNa, s→m 1.10 ± 0.20 1.22 ± 0.19 1.63 ± 0.36 1.59 ± 0.33
Values are means ± SE, n, no. of cell sheets. CF, cystic fibrosis; JNa, sodium flux. Fluxes are in μeq·cm−2·h−1 · CF human nasal epithelia.
*
P < 0.05, Student’s paired t-test.
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